Ariad Pharmaceuticals (NASDAQ:ARIA) was downgraded by stock analysts at Oppenheimer to a “market perform” rating in a report issued on Monday, Analyst Ratings Network.com reports.
Ariad Pharmaceuticals (NASDAQ:ARIA) opened at 2.67 on Monday. Ariad Pharmaceuticals has a 1-year low of $2.62 and a 1-year high of $24.59. The stock has a 50-day moving average of $16.37 and a 200-day moving average of $17.75. The company’s market cap is $494.2 million.
Ariad Pharmaceuticals (NASDAQ:ARIA) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.37) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.40) by $0.03. The company had revenue of $13.90 million for the quarter, compared to the consensus estimate of $11.11 million. During the same quarter last year, the company posted ($0.31) earnings per share. Ariad Pharmaceuticals’s revenue was up 4302.5% compared to the same quarter last year. On average, analysts predict that Ariad Pharmaceuticals will post $-1.61 earnings per share for the current fiscal year.
ARIA has been the subject of a number of other recent research reports. Analysts at William Blair downgraded shares of Ariad Pharmaceuticals to a “market perform” rating in a research note to investors on Monday. Separately, analysts at Guggenheim cut their price target on shares of Ariad Pharmaceuticals from $10.00 to $7.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. Finally, analysts at RBC Capital downgraded shares of Ariad Pharmaceuticals to a “sector perform” rating in a research note to investors on Friday. Two equities research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $14.19.
ARIAD Pharmaceuticals, Inc (NASDAQ:ARIA) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.